Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.